Viewing Study NCT00193362



Ignite Creation Date: 2024-05-05 @ 11:58 AM
Last Modification Date: 2024-10-26 @ 9:17 AM
Study NCT ID: NCT00193362
Status: COMPLETED
Last Update Posted: 2010-07-28
First Post: 2005-09-12

Brief Title: Study of Paclitaxel Carboplatin and Gemcitabine Versus Gemcitabine and Vinorelbine for Non-Small Cell Lung Cancer
Sponsor: SCRI Development Innovations LLC
Organization: SCRI Development Innovations LLC

Study Overview

Official Title: Phase III Randomized Study of Paclitaxel Carboplatin and Gemcitabine Versus Gemcitabine and Vinorelbine as First-Line Chemotherapy for Stage IIIB and IV Non-Small Cell Lung Cancer
Status: COMPLETED
Status Verified Date: 2010-07
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of this study is to compare the effectiveness of the three-drug combination paclitaxel carboplatin and gemcitabine to the two-drug combination gemcitabine and vinorelbine in patients with advanced Non-Small Cell Lung Cancer
Detailed Description: Upon determination of eligibility patients will be randomly assigned to one of two treatment arms

Paclitaxel Carboplatin Gemcitabine
Gemcitabine Vinorelbine

For ever 2 patients treated 1 will receive treatment A Paclitaxel Carboplatin Gemcitabine and 1 will receive treatment B Gemcitabine Vinorelbine The study is not blinded so both the patient and the doctor will know which treatment has been assigned

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
B9E-MC-X338 None None None
VNR-R47 None None None